The Breast Cancer International Research Group 006 (BCIRG-006) trial, which was the third part of the study, showed that PTEN loss in people with HER2+ BC is linked to a worse prognosis but not to TRS resistance [12]. This evidence concerns the gene ERBB2 and breast carcinoma.